Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EMIS, unsubscribe in one click. Privacy
EMIS holds $708,065 in cash and short-term investments (as of Jun 30, 2026) and burns about $119,907/quarter from operations, an estimated runway of 17.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
However, because the Company is required to complete its initial Business Combination or obtain an extension of the Combination Period by March 26, 2027, which falls within one year from the date these condensed financial statements are issued, or otherwise cease operations and liquidate, management has concluded that10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EMIS files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EMIS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →